Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard H Stanford

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
COPD|December 2, 2006
Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary diseaseAntonio Anzueto, Trent McLaughlin, Richard H Stanford
Treatments in Respiratory Medicine|August 25, 2006
Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US HospitalsRichard H Stanford, Yingjia Shen, Trent McLaughlin
Managed Care (Langhorne, Pa.)|May 16, 2018
Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database studySaurabh Nagar, Jeetvan Patel, Richard H Stanford
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 29, 2011
Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbationMay Hagiwara, Thomas E Delea, Richard H Stanford
Journal of Asthma and Allergy|January 10, 2013
Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthmaRichard H Stanford, Manan Shah, Anna O D'Souza
The Journal of Allergy and Clinical Immunology|July 12, 2002
The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonistDavid A Stempel, Lionel Pinto, Richard H Stanford
The Open Respiratory Medicine Journal|July 13, 2012
Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 yearsRichard H Stanford, Manan Shah, Sham L Chaudhari
Allergy and Asthma Proceedings|January 18, 2014
Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbationsMay Hagiwara, Thomas E Delea, Richard H Stanford
Clinical Therapeutics|May 10, 2005
A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combinationKaren L Rascati, Richard H Stanford, Rohit Borker
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 12, 2013
Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powderMay Hagiwara, Thomas E Delea, Richard H Stanford
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
COPD|December 2, 2006
Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary diseaseAntonio Anzueto, Trent McLaughlin, Richard H Stanford
Treatments in Respiratory Medicine|August 25, 2006
Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US HospitalsRichard H Stanford, Yingjia Shen, Trent McLaughlin
Managed Care (Langhorne, Pa.)|May 16, 2018
Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database studySaurabh Nagar, Jeetvan Patel, Richard H Stanford
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 29, 2011
Retrospective comparison of early versus late treatment with fluticasone propionate/salmeterol after an asthma exacerbationMay Hagiwara, Thomas E Delea, Richard H Stanford
Journal of Asthma and Allergy|January 10, 2013
Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthmaRichard H Stanford, Manan Shah, Anna O D'Souza
The Journal of Allergy and Clinical Immunology|July 12, 2002
The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonistDavid A Stempel, Lionel Pinto, Richard H Stanford
The Open Respiratory Medicine Journal|July 13, 2012
Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 yearsRichard H Stanford, Manan Shah, Sham L Chaudhari
Allergy and Asthma Proceedings|January 18, 2014
Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbationsMay Hagiwara, Thomas E Delea, Richard H Stanford
Clinical Therapeutics|May 10, 2005
A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combinationKaren L Rascati, Richard H Stanford, Rohit Borker
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 12, 2013
Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powderMay Hagiwara, Thomas E Delea, Richard H Stanford
Pageof 11